OTCMKTS:CXRXF ADVANZ PHARMA (CXRXF) Stock Price, News & Analysis $17.06 0.00 (0.00%) (As of 06/10/2021) Add Compare Share Share Stock Analysis Stock Analysis About ADVANZ PHARMA Stock (OTCMKTS:CXRXF) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ADVANZ PHARMA alerts:Sign Up Key Stats Today's Range$17.06▼$17.0650-Day Range$17.06▼$17.0652-Week Range$2.13▼$18.00Volume39 shsAverage Volume11,851 shsMarket Capitalization$834.46 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.Read More… Algo Trading Is Here 🔥 (Ad)One trade alert each day backed by powerful technology, yours free. For $0 you can get access to one daily stock picked directly from StocksToTrade’s algo-powered system.>> Click here to sign up & get the next 🔥alert sent directly to your phone << Receive CXRXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ADVANZ PHARMA and its competitors with MarketBeat's FREE daily newsletter. Email Address CXRXF Stock News HeadlinesPHAT Phathom Pharmaceuticals, Inc.April 7, 2024 | seekingalpha.comDimerix completes ‘highly strategic’ $20m cap raise to advance ACTION3 Phase 3 trialMarch 12, 2024 | msn.comThe real reason Elon is fully endorsing TrumpElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. October 31, 2024 | Porter & Company (Ad)Interim results for Dimerix’s Phase 3 trial of DXB-200 for FSGS kidney disease on track for release in March 2024February 28, 2024 | msn.comDimerix receives $10.7 million upfront payment from Advanz PharmaNovember 7, 2023 | msn.comApplied Therapeutics adds 19% on partnership with Advanz Pharma for lead assetJanuary 4, 2023 | msn.comMADE in America Act is critical for the pharmaceutical industrySeptember 27, 2022 | dallasnews.comPolyPid to get $2.6M upfront under license deal with Advanz for D-PLEX in EuropeAugust 5, 2022 | seekingalpha.comSee More Headlines CXRXF Stock Analysis - Frequently Asked Questions How have CXRXF shares performed this year? ADVANZ PHARMA's stock was trading at $17.06 at the beginning of the year. Since then, CXRXF stock has increased by 0.0% and is now trading at $17.06. View the best growth stocks for 2024 here. How do I buy shares of ADVANZ PHARMA? Shares of CXRXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:CXRXF CUSIPN/A CIKN/A Webwww.advanzpharma.com Phone44-20-8588-9100FaxN/AEmployees429Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,860,000.00 Net Margins-15.31% Pretax MarginN/A Return on EquityN/A Return on Assets-4.38% Debt Debt-to-Equity Ratio257.04 Current Ratio2.39 Quick Ratio1.61 Sales & Book Value Annual Sales$525.58 million Price / Sales1.59 Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book106.63Miscellaneous Outstanding Shares48,913,000Free FloatN/AMarket Cap$834.46 million OptionableNot Optionable BetaN/A Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report This page (OTCMKTS:CXRXF) was last updated on 10/31/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredCNBC’s ‘Prophet’ issues urgent Fed warning"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ADVANZ PHARMA Corp. Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share ADVANZ PHARMA With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.